Answers are grounded in this paper and cite their sources.
Despite observed benefits of current treatments, several burdensome symptoms persist in people living with spinal muscular atrophy (SMA). Fatigue is consistently indicated as a top unmet need by the SMA community. Historically ascribed as an inevitable consequence of underlying muscle weakness, fatigue is now recognized as central to the lived SMA experience, and several efforts have been made to better characterize it. As in other disorders, the study of fatigue in SMA is complicated by inconsistencies in terminology and nomenclature, a challenge compounded by the heterogeneous language patients use to describe their experiences. Without shared language and conceptual frameworks, progress toward an improved understanding of fatigue has been impeded. Critical to this aim is distinguishing between related but distinct constructs: perceived fatigue, a subjective multidimensional experience, and fatigability, a measurable decline in motor output or sustained activity. Both are prominent in SMA, but their biological causes remain unclear. Here, we draw on available evidence and the perspectives of experts, community stakeholders, caregivers, and patients to propose a uniform, collaboratively developed methodology that aims to advance SMA fatigue research and clinical management. This review outlines a roadmap to enhance identification of biological mechanisms and harmonize assessment tools, ultimately leading to a breakthrough in the treatment of fatigue. This iterative process is likely to extend beyond SMA and yield similar benefits in related neuromuscular conditions.
No takes yet. Share an insight, caveat, or question.
Rodriguez-Torres et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: